Press Releases

Cannasat and IntelGenx Announce Positive Phase 1(b) Results: Improved buccal tablet outperforms oral dronabinol

Marketwire, April 14, 2022

TORONTO – Cannasat Therapeutics Inc. (“Cannasat”) (TSX-V: CTH), and its development partner IntelGenx Corp. (TSX-V: IGX and OTCBB: IGXT) ("IntelGenx"), today announced positive results for the Phase 1(b) clinical trial of Relivar, the first buccal dronabinol drug delivery product, which was developed using IntelGenx’ proprietary AdVersa buccal delivery technology.  Buccal delivery allows for drug absorption from the mouth directly into the bloodstream as opposed to the intestinal tract absorption seen with oral tablet technologies.

“These results conclusively show successful delivery of dronabinol in a buccal dosage form,” said David Hill, Chief Executive Officer of Cannasat.  “This study proves to us that Relivar has the potential to be a commercially viable product for treatment of neuropathic pain, chemotherapy nausea/vomiting, and possibly other conditions.  The cumulative size of these markets exceeds $4 billion annually with the neuropathic pain market experiencing the most growth in recent years.  Relivar’s buccal delivery of dronabinol will allow for more flexible dosing with potentially fewer side effects.”

In this latest clinical trial, Relivar delivered twice the amount of dronabinol into the bloodstream versus the reference drug Marinol (as measured by AUC) with no increase in adverse events.  The randomized, single dose, double crossover study compared Cannasat’s Relivar to the reference oral dosage form of dronabinol (Marinol) at 2.5 mg in healthy volunteers.  Relivar was well-tolerated with no adverse events noted in this study.  Relivar met its primary goal of delivering a greater dose of the drug through the buccal mucosa versus the reference compound, Marinol, which is swallowed and has an intestinal absorption mechanism.  Relivar also showed nearly a 50% reduction in the ratio of 11-OH-THC to the parent drug versus oral dronabinol in the same subjects.  Literature suggests that the 11-OH-THC metabolite, which is also a marker of absorption in the gut, is responsible for the pronounced CNS adverse events of oral Marinol (or dronabinol).  Relivar also showed an extended absorption profile which may be advantageous for more convenient dosing. 

Hill also outlined Cannasat’s next steps: “We now plan to confirm our 505b2 regulatory pathway via a pre-IND meeting with the US FDA.”

“We are particularly excited about the results of this study because it proves the effectiveness ofAdVersa, our proprietary buccal delivery technology," said Dr. Horst Zerbe, President and Chief Executive Officer of IntelGenx.  “We have again demonstrated our ability to improve existing medications. I have the utmost confidence in the IntelGenx technologies to deliver the desired results in a wide range of possibilities.  We are especially pleased to have this opportunity to team up with Cannasat in developing an improved delivery form for dronabinol. ”


About Cannasat Therapeutics

Cannasat is a clinical stage pharmaceutical company developing products to treat neurological disorders such as neuropathic pain and schizophrenia. Cannasat currently has two new drugs in its pipeline: Relivar (formerly CAT 310) and Modulyn (formerly CAT 320).   Over the next 12 months Cannasat plans to advance Relivar and Modulyn with further clinical testing and is positioning itself to enter marketing agreements with select Pharma partners.  Pharma collaborations will create a pathway towards the future commercialization, as well as provide important new investment to develop our pipeline of additional CNS/neurology product candidates.  More information about Cannasat (CTH : TSXV) is available at


About IntelGenx Corp.

IntelGenx Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films.  The Company's research and development pipeline includes products for the treatment of pain, hypertension, osteoarthritis, and depressive disorders. More information is available about the company at


Contact Information

Cannasat Therapeutics Inc.
Andrew Williams
W: (416) 703-2449 (Ext. 253)
F: (416) 703-8752
[email protected]

IntelGenx Corp.
Dr. Horst G. Zerbe
President and CEO
T: (514) 331-7440 (Ext. 201)
F: (514) 331-0436
[email protected]


Cautionary Note Regarding Forward Looking Statements

This document may contain forward-looking information about IntelGenx’s and/or Cannasat’s operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx’s and / or Cannasat’s plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.  Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's and Cannasat’s actual results could differ materially from those expressed or implied by these forward-looking statements.  Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K for the fiscal year ended December 31, 2008, filed with the United States Securities and Exchange Commission and available at  The companies assume no obligation to update any such forward-looking statements.

The TSX Venture Exchange Inc. and OTCBB have not reviewed and do not accept responsibility for the adequacy or accuracy of this press release.

Top of Page

Horizonatal Rule
About CynapsusLine SeperationAPL-130277 ProductLine SeperationParkinson's DiseaseLine SeperationInvestor RelationsLine SeperationContact & LegalLine Seperation

Copyright 2016, Cynapsus Therapeutics Inc.
All rights reserved.

Traded on